

Efavirenz + lamivudine + tenofovir

Essential medicine status

General description

A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.

INN

Efavirenz + lamivudine + tenofovir

ATC codes

[J05AR11](#)

Medicine type

Chemical agent

EML status history

First added in 2017 ([TRS 1006](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Changed in 2021 ([TRS 1035](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Therapeutic equivalent for

[efavirenz + emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia

[Efavirenz + lamivudine + tenofovir](#)

DrugBank

[Efavirenz](#),

[Lamivudine](#),

[Tenofovir disoproxil](#)

Recommendations

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)